Goldman Sachs Group Inc. cut its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 21.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 79,724 shares of the company’s stock after selling 21,978 shares during the period. Goldman Sachs Group Inc.’s holdings in Karyopharm Therapeutics were worth $1,024,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Russell Investments Group Ltd. purchased a new position in shares of Karyopharm Therapeutics during the fourth quarter worth approximately $343,000. State Street Corp boosted its position in shares of Karyopharm Therapeutics by 6.6% in the fourth quarter. State Street Corp now owns 406,103 shares of the company’s stock worth $3,820,000 after buying an additional 25,015 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Karyopharm Therapeutics by 347.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 261,055 shares of the company’s stock worth $2,454,000 after buying an additional 202,714 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its position in shares of Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock worth $206,000 after buying an additional 2,460 shares during the last quarter. Finally, Teachers Advisors LLC boosted its position in shares of Karyopharm Therapeutics by 15.0% in the fourth quarter. Teachers Advisors LLC now owns 41,436 shares of the company’s stock worth $389,000 after buying an additional 5,419 shares during the last quarter. Institutional investors own 57.46% of the company’s stock.

Shares of Karyopharm Therapeutics Inc. (NASDAQ KPTI) traded up 3.64% on Friday, reaching $8.55. The company had a trading volume of 153,270 shares. Karyopharm Therapeutics Inc. has a one year low of $6.27 and a one year high of $14.63. The company’s market capitalization is $403.03 million. The company’s 50-day moving average is $9.11 and its 200-day moving average is $10.01.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.64) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. During the same quarter in the previous year, the business earned ($0.84) EPS. The company’s quarterly revenue was down 95.0% on a year-over-year basis. Equities research analysts predict that Karyopharm Therapeutics Inc. will post ($2.69) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/goldman-sachs-group-inc-cuts-position-in-karyopharm-therapeutics-inc-nasdaqkpti/1478277.html.

A number of research analysts have recently commented on KPTI shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $18.00 price target on shares of Karyopharm Therapeutics in a research note on Monday, May 15th. ValuEngine cut Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 25th. Robert W. Baird reiterated an “outperform” rating and issued a $15.00 price target on shares of Karyopharm Therapeutics in a research note on Tuesday, July 4th. Zacks Investment Research upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research note on Thursday, July 6th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $14.56.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Want to see what other hedge funds are holding KPTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Karyopharm Therapeutics Inc. (NASDAQ:KPTI).

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.